Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
You must be a Standard 1 Year member to access this content.
